The estimated Net Worth of Arthur A Levin is at least $6.51 Millón dollars as of 19 August 2024. Arthur Levin owns over 5,000 units of Stoke Therapeutics stock worth over $292,294 and over the last 5 years he sold STOK stock worth over $5,938,794. In addition, he makes $282,528 as Independent Director at Stoke Therapeutics.
Arthur has made over 21 trades of the Stoke Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of STOK stock worth $6,200 on 19 August 2024.
The largest trade he's ever made was selling 100,000 units of Stoke Therapeutics stock on 12 June 2024 worth over $3,807,000. On average, Arthur trades about 13,098 units every 40 days since 2019. As of 19 August 2024 he still owns at least 19,830 units of Stoke Therapeutics stock.
You can see the complete history of Arthur Levin stock trades at the bottom of the page.
Dr. Arthur A. Levin Ph.D. serves as Independent Director of the Company. Since January 2014, Dr. Levin has served as Chief Scientific Officer at Avidity Biosciences, Inc., a biotechnology company. From April 2012 to January 2014, Dr. Levin served as Executive Vice President at miRagen Therapeutics, Inc., an RNA-focused therapeutics company. Prior to joining miRagen Therapeutics, Inc., Dr. Levin served in various senior management positions at Santaris Pharma A/S Corp., a biopharmaceutical company, and Ionis Pharmaceuticals, Inc., a public, RNA-focused biopharmaceutical company. Dr. Levin holds a B.S. in Biology from Muhlenberg College and a Ph.D. in Toxicology from the University of Rochester. Levin is qualified to serve on our Board of Directors because of his industry experience, including his expertise in nucleic-acid-based therapeutics.
As the Independent Director of Stoke Therapeutics, the total compensation of Arthur Levin at Stoke Therapeutics is $282,528. There are 12 executives at Stoke Therapeutics getting paid more, with Stephen Tulipano having the highest compensation of $1,176,400.
Arthur Levin is 65, he's been the Independent Director of Stoke Therapeutics since 2015. There are 4 older and 16 younger executives at Stoke Therapeutics. The oldest executive at Stoke Therapeutics, Inc. is Dr. Edward M. Kaye M.D., Ph.D., 72, who is the CEO & Director.
Arthur's mailing address filed with the SEC is C/O AVIDITY BIOSCIENCES, INC., 10578 SCIENCE CENTER DRIVE, SUITE 125, SAN DIEGO, CA, 92121.
Over the last 5 years, insiders at Stoke Therapeutics have traded over $49,612,288 worth of Stoke Therapeutics stock and bought 4,288,550 units worth $94,976,062 . The most active insiders traders include Group, Llc Green Jeremy Red..., Investments, Lpwong Roderic... y Trust Blue Horizon Enterpri.... On average, Stoke Therapeutics executives and independent directors trade stock every 23 days with the average trade being worth of $1,639,987. The most recent stock trade was executed by Barry Ticho on 3 September 2024, trading 10,000 units of STOK stock currently worth $6,000.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Stoke Therapeutics executives and other stock owners filed with the SEC include: